Wanted to go with "Thunderbirds are GO", but though it was best...

Wanted to go with "Thunderbirds are GO", but though it was best to stick with Dimerix.

With DXB being oversubscribed by $2 million (after allocations were scaled back), I think we are all very pleased to know that DXB is now free of any financial burden and can confidently proceed into Phase 2B with their lead compound DMX-200. After the funds were confirmed last week a few here on HC speculated at how valuable DXB will become? Only time will tell whether DXB will be worth more or less than VLA's $500 million take over offer.

For now I'm curious to get opinions on how others think DMX-200 will be developed/marketed?

I'm no doctor so please correct me if I'm inaccurate, but from what I understand DXB is looking to develop DMX-200 on 2 fronts:

1) Phase 2B trial of DMX-200 for rare kidney disease FSGS which will start before end March 2018, and

2) Phase 2B trial of DMX-200 for Diabetic Nephropathy (think I read somewhere that this is now 2019??).

So what do you think the plan is?

As initial/final results come in for FSGS, does DXB do a deal using Diabetic Nephropathy as an upside carrot (as the results from Phase 2A where positive, albeit from a small test group), or can they do a deal for FSGS only and continue separately with Diabetic Nephropathy?

Thoughts?

Cheers
Pies